|
Emergent Biosolutions Inc (NYSE: EBS) |
|
Emergent Biosolutions Inc
EBS's Fundamental analysis
Select the Comparisons :
|
|
Select the Ratio:
|
|
|
Emergent Biosolutions Inc 's sales fell
by -29.41 % in IV. Quarter 2024 from the same quarter a year ago.
Ranking at No. 1710
Major Pharmaceutical Preparations industry recorded
growth of revenues by 11.88 %
Emergent Biosolutions Inc net loss decreased from $-53 millions, to $-31 millions in IV. Quarter 2024,
• More on EBS's Growth
|
|
Emergent Biosolutions Inc realized a net loss in trailing twelve months.
Emergent Biosolutions Inc realized cash reduction of $ -0.12 per share in trailing twelve-month period. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Company's Price to Sales ratio is at 0.29.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.34.
• More on EBS's Valuation
|
|
|
|
|
Emergent Biosolutions Inc realized net loss in trailing twelve months.
Emergent Biosolutions Inc realized cash outflow of $ -0.12per share in trailing twelve-month period. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Company's Price to Sales ratio is at 0.29.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.34.
Emergent Biosolutions Inc Price to Book Ratio is at 0.63 lower than Industry Avg. of 91.08. and higher than S&P 500 Avg. of 0.01
• More on EBS's Valuation
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2025 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com